To evaluate the Safety and medicinal effectiveness of Unani formulations Damavi in SÅ«â?? al Qinya(Anaemia)

Phase 2

• Conditions: Health Condition 1: D509- Iron deficiency anemia, unspecifiedHealth Condition 2: null- SÅ«â?? al-Qinya(Anaemia)

• Registration Number: CTRI/2015/10/006273
• Lead Sponsor: Central Council for Research in Unani Medicine New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

•SÅ«â?? al-Qinya(anaemia) with Haemoglobin level 8-12 g/dL in men and 8-11 g/dL in women with or without any of the following signs and symptoms:

�Shuhūb (Pallor)

ï?§NaqÄ?hat (Weakness)

ï?§Iâ??yÄ?â?? (Fatigue)

ï?§â??Usr al-Tanaffus (Dyspnoea)

Exclusion Criteria

1.Patients with severe anaemia (Hb <8 g/dL)

2.Patients having anaemia with any associated severe complications

3.Patients having occult blood positive on stool examination.

4.Patients with sickle cell anaemia, aplastic anaemia, sideroblasticanaemia, anaemia due to malignancies, thalassaemia, hereditary spherocytosis, and lead poisoning.

5.Patients with chronic diseases requiring long-term treatment such as diabetes mellitus, tuberculosis, HIV infection, lukaemia, endocrine disorders, haemorrhagic diathesis (hemophilia, ITP), bleeding piles, menorragia, metrorrhagia or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data.

6.Patients with concurrent serious hepatic, cardiac, renal or pulmonary dysfunction.

7.Pregnant and lactating women

8.H/o addiction (alcohol, drugs)

9.H/o Hypersensitivity to the study drug or any of its ingredients.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of SÅ«â?? al-Qinya(Anaemia)Timepoint: 8 weeks

Secondary Outcome Measures

Name	Time	Method
Hematological and biochemical assessments for safetyTimepoint: 8 weeks